Analysis of oncological diseases in tumor-associated localized scleroderma

Relevance. Authors have repeatedly corresponded about cases indicating a link between localized scleroderma and malignant diseases. However, there are very few studies of associations with specific types of cancer.

Goal. To study the types of malignant diseases associated with localized scleroderma.

Materials and methods. A retrospective study was conducted of 69 cases of tumor-associated scleroderma treated in 2022–2023. The average age of the patients was 64.6±1.72 years. The time interval between the onset of two diseases is no more than 10 years.

Results. More often than others, there is an association with breast cancer (36.23%), uterine body cancer (14.71%), ovarian cancer (13.04%) and basal cell carcinoma (11.77%). In most cases, the malignant process made its debut first. Skin symptoms manifested primarily in all cases of basal cell carcinoma of the skin, thyroid cancer, rectal ampoule cancer. Cases of breast cancer and uterine cancer demonstrate both the primary debut of oncology and localized scleoderma. It was revealed that an average of 5.82±1.2 years elapse between the manifestation of the malignant process and the clinical signs of localized scleroderma. With the primary clinical manifestation of the skin process, an average of 4.13±1.22 years pass before the detection of oncology. In cases of chemotherapy, 6.3 ± 1.96 years pass before the manifestation of the skin process.

Conclusion. Understanding the clinical features of the tumor-associated form of localized scleroderma will help in early diagnosis, prolongation and improvement of the quality of life of patients.

1. Dvornicov A.S. Neuroendocrine changes in patients with scleroderma-associated form tumor. Vestnik novyhmedicinskih tehnologij. 2013; № 1: P. 23. (In Russ.).]

2. Ovsiy O.G., Gens G.P., Korobkova L.I., Malyavin A.G. Paraneoplastic skin changes (acanthosis nigricans maligna) in generalized cervical cancer (clinical observation). Doktor. Ru.2014; № 9–10: P. 25–27. (In Russ.).

3. Dvornicov A.S. Skin manifestations at tumor associated autoimmune diseases with. Vestnik novyhmedicinskih tehnologij. 2011. Т. XVIII, № 2: P. 415. (In Russ.).

4. Jedlickova H., Durčanská V., Vašků V. Paraneoplastic Scleroderma: Are There Any Clues? Acta Dermatovenerol Croat. 2016. Apr; 24 (1): 78–80. PMID: 27149136

5. Zahn C.A., Feldmeyer L., Blum R., Mainetti C. Post-Irradiation Morphea of the Breast in a Patient with Subacute Cutaneous Lupus Erythematosus: Case Report and a Literature Review. Case Rep Dermatol. 2022 May 30; 14 (2): 144–150. DOI: 10.1159/000524514. PMID: 35813833; PMCID: PMC9209955

6. Gonzalez-Ericsson P.I., Estrada M.V., Al-Rohil R., Sanders M.E. Post-irradiation morphoea of the breast: a case report and review of the literature. Histopathology. 2018 Jan; 72 (2): 342–350. DOI: 10.1111/his.13343. Epub 2017 Nov 7. PMID: 29110314

7. Künzel S.R., Günther C. Postradiogene Morphea – eineÜbersicht [Radiation-induced morphea-an overview]. Dermatologie (Heidelb). 2024 Mar; 75 (3): 214–217. German. DOI: 10.1007/s00105 023 05292 6. Epub 2024 Jan 19. PMID: 38240813

8. Partl R., Regitnig P., Lukasiak K., Winkler P., Kapp K.S. Incidence of Morphea following Adjuvant Irradiation of the Breast in 2,268 Patients. Breast Care (Basel). 2020 Jun; 15 (3): 246–252. DOI: 10.1159/000502030. Epub 2019 Aug 16. PMID: 32774218; PMCID: PMC7383247

9. de Giorgi V., Santi R., Grazzini M., Papi F., Gori A., Rossari S., Massi D., Lotti T. Synchronous angiosarcoma, melanoma and morphea of the breast skin 14 years after radiotherapy for mammary carcinoma. Acta Derm Venereol. 2010 May; 90 (3): 283–6. DOI: 10.2340/00015555–0841. PMID: 20526547

10. Farrugia S., Mercieca L., Betts A., Refalo N., Boffa M.J. Scleroderma Secondary to Pembrolizumab: A Case Report and Review of 19 Cases of Anti-PD 1-Induced Scleroderma. Case Rep Oncol. 2023 Sep 6; 16 (1): 846–856. DOI: 10.1159/000533373. PMID: 37900813; PMCID: PMC10601745

11. Acar A., Oraloglu G., Yaman B., Karaarslan I. Nivolumab-induced plaque morphea in a malign melanoma patient. J Cosmet Dermatol. 2021 Aug; 20 (8): 2645–2647. DOI: 10.1111/jocd.13914. Epub 2020 Dec 28. PMID: 33355973

12. Sibaud V. Dermatologic Reactions to Immune Checkpoint Inhibitors: Skin Toxicities and Immunotherapy. Am J Clin Dermatol. 2018 Jun; 19 (3): 345–361. DOI: 10.1007/s40257 017 0336 3. PMID: 29256113

13. Shostak N.A., Klimenko A.A., Demidova N.A., Andriyashkina D. Yu. Scleroderma as a paraneoplastic syndrome and tumors associated with scleroderma. The Clinician. 2020; 14 (1–2): 55–61. (In Russ.). https://doi.org/10.17650/1818 8338 2020 14 1 2 55 61

14. Ruiz-Matta J.M., Flores-Bozo L.R., Dominguez-Cherit J. Metastatic Squamous Cell Carcinoma in a Patient with Disabling Pansclerotic Morphea of Childhood. Pediatr Dermatol. 2017 Jul; 34 (4): e164-e167. DOI: 10.1111/pde.13160. Epub 2017 May 23. PMID: 28543434

15. Koch K., Grayson W. Carcinoid Syndrome-Induced Scleroderma-Like Disease. Dermatopathology (Basel). 2019 Jun 26; 6 (2): 99–104. DOI: 10.1159/000496388. PMID: 31700850; PMCID: PMC6827453

16. Resources and activities of medical organizations of dermatovenereological profile. Incidence of sexually transmitted infections, contagious skin diseases and skin diseases for 2017–2018 (statistical materials). Moscow 2019. P. 208. (In Russ.).

17. https://rosstat.gov.ru/folder/13721.